Genelabs Withdraws Prasterone Application In Europe; U.S. Confirmatory Trial Stays On Schedule
This article was originally published in The Pink Sheet Daily
Executive SummaryThe company is seeking a partner for Europe to assist in future regulatory discussions after data were deemed insufficient. An additional U.S. trial confirming prasterone's effects on bone loss is expected to be complete by year-end.
You may also be interested in...
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.